PKD2 antibody (C-Term)
Quick Overview for PKD2 antibody (C-Term) (ABIN360330)
Target
See all PKD2 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Specificity
- This antibody recognizes Protein Kinase D2 (PKD2).
-
Cross-Reactivity (Details)
- Species reactivity (tested):Human.
-
Purification
- Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
-
Immunogen
- This PKC-D2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of Human PKD2. Genename: PRKD2
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
ELISA: 1/1,000. Western blotting: 1/100-1/500. Immunohistochemistry on Paraffin Sections: 1/50-1/100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) Sodium Azide as preservative.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
- PKD2 (Protein Kinase D2 (PKD2))
-
Alternative Name
- PRKD2 / PKD2
-
Background
- PKD2, a member of the polycystin family, functions as a calcium permeable cation channel. PKD1 and PKD2 may function through a common signaling pathway that is necessary for normal tubulogenesis. PKD2 interacts with PKD1, potentially through the C-terminal region. PKD1 requires the presence of PKD2 for stable expression. PKD2 also interacts with CD2AP. This protein is strongly expressed in ovary, fetal and adult kidney, testis, and small intestine, but is not detected in peripheral leukocytes. Defects in PKD2 are the cause of autosomal dominant polycystic kidney disease type II (ADPKD-2) which represent approximately 15 % of cases of autosomal dominant polycystic kidney disease, a common autosomal dominant genetic disease affecting about 1 out 1000 individuals. ADPKD is characterized by progressive formation and enlargement of cysts in both kidneys, typically leading to end-stage renal disease in adult life. Cysts also occurs in the liver and other organs. All mutations, scattered between exons 1 and 11, result in a truncated PKD2 that lacks both the calcium-binding EF-hand domain and the two cytoplasmic domains required for the interaction of PKD2 with PKD1 and with itself. ADPKD type II is clinically milder than ADPKD type I, but it has a deleterious impact on overall life expectancy.Synonyms: HSPC187, PKC-D2, Serine/threonine-protein kinase D2, nPKC-D2
-
Gene ID
- 25865
-
NCBI Accession
- NP_001073349
-
UniProt
- Q9BZL6
-
Pathways
- cAMP Metabolic Process, Maintenance of Protein Location, Negative Regulation of Transporter Activity
Target
-